Ryan Specialty (NYSE:RYAN) Initiated coverage at Barclays

Stock analysts at Barclays initiated coverage on the stock Ryan Specialty (NYSE:RYAN – Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat reports. The firm set an “overweight” rating and a $76.00 price target on the stock. Barclays’ price objective indicates a potential upside of 18.07% from the company’s current price.

A number of other research analysts have recently issued reports on the company. Wells Fargo & Company boosted their price target on Ryan Specialty from $60.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. UBS Group raised their target price on shares of Ryan Specialty from $67.00 to $76.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Goldman Sachs Group upped their price target on shares of Ryan Specialty from $58.00 to $64.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. JPMorgan Chase & Co. lifted their price objective on shares of Ryan Specialty from $54.00 to $56.00 and gave the company an “underweight” rating in a research note on Friday, August 2nd. Finally, Bank of America initiated coverage on shares of Ryan Specialty in a research note on Wednesday, May 22nd. They set a “buy” rating and a $67.00 price target for the company. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. Ryan Specialty currently has a consensus rating of “Hold” and an average target price of $63.40, based on data from MarketBeat.com.

Read our latest research report on RYAN

Ryan Specialty Stock 0.5%

Shares of RYAN stock opened at $64.37 on Wednesday. The stock has a market cap of $16.83 billion, a P/E ratio of 121.46, a PEG ratio of 1.53 and a beta of 0.62. The company has a current ratio of 1.09, a quick ratio of 1.09, and a debt-to-equity ratio of 1.81. Ryan Specialty has a 12-month low of $41.49 and a 12-month high of $69.03. The company’s 50-day moving average is $61.64, and its two-hundred-day moving average is $56.09.

Ryan Specialty (NYSE:RYAN – Get Free Report ) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.02. The firm had revenue of $695.40 million during the quarter, compared to analysts’ expectations of $695.56 million. Ryan Specialty had a net margin of 10.21% and a return on equity of 48.08%. Ryan Specialty’s quarterly revenue was up 18.9% compared to the same quarter last year. In the same period last year, the company earned $0.45 per share. research analysts expect that Ryan Specialty will post 1.81 earnings per share for the current fiscal year.

Indoor activity

In related news, Chairman Timothy William Turner sold 2,000,000 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $62.45, for a total value of $124,900,000.00. Following the completion of the transaction, the chairman now directly owns 8,095 shares of the company’s stock, valued at approximately $505,532.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC’s website. In other Ryan Specialty news, Director Nicholas Dominic Cortezi sold 1,500 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $65.02, for a total value of $97,530.00. Following the sale, the director now owns 25,123 shares of the company’s stock, valued at $1,633,497.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC’s website. Also, Chairman Timothy William Turner sold 2,000,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $62.45, for a total transaction of $124,900,000.00. Following the transaction, the chairman now directly owns 8,095 shares of the company’s stock, valued at $505,532.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 2,107,136 shares of company stock worth $131,860,032. Company insiders hold 11.10% of the company’s shares.

Ryan Specialty Institutional Trading

A number of large investors have recently made changes to their positions in RYAN. Nebula Research & Development LLC purchased a new stake in shares of Ryan Specialty during the fourth quarter valued at approximately $1,284,000. Capstone Investment Advisors LLC purchased a new stake in Ryan Specialty in the 1st quarter worth about $727,000. Securian Asset Management Inc. purchased a new position in Ryan Specialty in the second quarter valued at $474,000. Embree Financial Group purchased a new position in shares of Ryan Specialty in the first quarter worth $1,701,000. Finally, Geneva Capital Management LLC boosted its holdings in shares of Ryan Specialty by 12.0% in the first quarter. Geneva Capital Management LLC now owns 475,552 shares of the company’s stock worth $26,393,000 after buying an additional 50,947 shares in the last quarter. Institutional investors and hedge funds own 84.82% of the company’s shares.

Ryan Specialty Company Profile

(Get a free report)

Ryan Specialty Holdings, Inc operates as a service provider of specialty products and solutions to insurance brokers, agents and carriers in the United States, Canada, the United Kingdom, Europe and Singapore. It provides distribution, underwriting, product development, administration and risk management services, acting as a wholesale broker and managing underwriter.

See Also

Get news and reviews for Ryan Specialty Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ryan Specialty and related companies with MarketBeat.com’s FREE daily email newsletter.